One of the major benefits of In-Vitro Diagnostic Research (IVDr) by NMR is its reproducibility and transferability. This enables researchers across the globe to exchange data based on SOPs embedded in the IVDr Platform solution. In addition it allows integrated statistics on worldwide results as well as retrospective analysis of already acquired data with new analysis routines. All this leads to a significant reduction of cost. Using the IVDr by NMR platform and established standard operating procedures, it is also possible to offer remote analysis such as automatic urine quantification and lipoprotein subclass analysis on serum and plasma.
Prof. Dr. med. Friedrich K. Trefz of University Childrens Hospital Heidelberg, Germany is in the process of developing a selective screening program for IEM using NMR as a first line method. Furthermore he evaluates its efficiency to GC/MS in a routine setting of the selective screening laboratory. In this webinar, he will report of the promising first results of this program.